News

At the recent ASRS meeting in New York, Aleksandra Rachitskaya, MD, of the Cleveland Clinic Cole Eye Institute, presented End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD.

The brain structures with most changes coincide with those which are altered most in Alzheimer’s, according to a study by researchers at the Universidad Complutense de Madrid in Spain.

Matthew Emanuel, MD, of Glaucoma Associates of Texas, discusses some of the current trends in cataract surgery. He notes it is something that everyone deals with as they get older. It also can be an issue for pediatric patients. Emanuel also notes that it is important for physicians to be able to educate their patients on the disease.

Tarsus Pharmaceuticals has enrolled the first patient in a Phase 2a clinical trial studying TP-03 for the treatment of meibomian gland disease in patients diagnosed with Demodex mites.

The project marks the Orbis Flying Eye Hospital's first return to in-person programming since the start of the pandemic.

A multi-institutional effort led by researchers at the University of Pennsylvania is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in patients with vision disorders.

The annual Mission Cataract program allows staff to extend its mission to people who need assistance due to unfortunate circumstances.

According to a new study from New York Eye and Ear Infirmary of Mount Sinai, a new, non-invasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss.

According to the company, AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease.

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

A novel regimen may represent an improvement over current methods of handling postsurgical pain in procedures that require corneal epithelial debridement, according to investigators.

Symptoms in the eye may not be substantial in patients with COVID-19.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study.

Two studies conducted in collaboration with Orbis International explore how providing free glasses to children improves their ability to learn in school and that addressing visual impairment in children can alleviate depression and anxiety.

The discovery of molecular signatures of age-related macular degeneration will help with better diagnosis and treatment of this progressive eye disease.

Investigators discuss the evolution of innovative technology for the hearing impaired and how vision can play a role.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Several issues may restimulate the virus in those patients with prior exposure.

The Grail study finds the device can offer positive outcomes for patients.

Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.

Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatments.

Behin Barahimi, MD, discusses some current trends in the treatment of dry eye disease. An oculoplastic, orbital and reconstructive surgeon, she is a member of the faculty at Vanderbilt Eye Institute.

Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray and provided an update on the commercial performance of the spray in the United States. According to the company, its expanded patient access programs include more eligible patients with dry eye disease.

Gareth Lema, MD, PhD, discusses an innovative eye stroke program at Mount Sinai Health System that involves collaboration among ophthalmologists, the stroke service, and emergency department physicians.